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AntiviralsThe 5′ untranslated region (5′UTR) of hepatitis C virus (HCV) is structured into four domains (I–IV) with nu-
merous genotype-speciﬁc nucleotides. It is unknown whether the polymorphisms confer genotype-speciﬁc
functions to the 5′UTR. Using viable JFH1-based Core-NS2 recombinants, we developed and characterized
HCV genotypes 1–7 recombinants with highly diverse 5′UTRs (genotypes 1a and 3a), 2a recombinants (J6/
JFH1) with 5′UTR of genotypes 1–6 or with heterotypic chimeric (1a/3a and 3a/1a) 5′UTR domains I, II or
III, and 1a recombinants with 5′UTR domain I of genotypes 1–6. All were fully functional in Huh7.5 cells;
therefore, the 5′UTR apparently functions in a non-genotype-speciﬁc manner in HCV production in vitro.
However, adenine at the 5′-terminus was required. We demonstrated that J6/JFH1 with 5′UTR of genotypes
1–6 responded similarly to interferon-α2b. This study provides novel insight into the role of the 5′UTR in the
HCV life cycle and facilitates HCV basic research and testing of 5′UTR-targeting antivirals.
© 2011 Elsevier Inc. All rights reserved.Introduction
The hepatitis C virus (HCV) is classiﬁed in the genus Hepacivirus
within the Flaviviridae family. The viral genome is a ~9.6 kb
positive-sense single-stranded RNA consisting of a single open read-
ing frame (ORF) ﬂanked by 5′ and 3′ untranslated regions (UTR)
(Moradpour et al., 2007). The 5′UTR is one of the most conserved re-
gions of the HCV genome, consisting of ~341 nucleotides. The 5′UTR
is predicted to form four major domains (I–IV) (Fig. 1A), with struc-
tures largely conserved among HCV genotypes, GB virus B (GBV-B),
and pestiviruses (Brown et al., 1992; Bukh et al., 1992; Honda et al.,
1999a). Domain I contains one stem-loop structure (SLI) (Honda
et al., 1999a) and two adjacent microRNA 122 (miR-122) binding
sites and their upstream nucleotides that were recently identiﬁed
(Figs. 1A and B) (Jopling et al., 2005, 2008; Machlin et al., 2011).
Domains II and III contain multiple stems and apical loops; domain
IV extends up to 10 nucleotides downstream of the start codon AUG
in the core coding sequence (Honda et al., 1999a). Domains I and II
are essential for HCV RNA replication, which is likely to be regulated
by domain III (Friebe et al., 2001; Kim et al., 2002; Luo et al., 2003;
Reusken et al., 2003). Domains II, III and IV comprise the internal ribo-
some entry site (IRES) that initiates cap-independent translation of
HCV RNA, which might be modulated by SLI, Core coding sequencesiseases, Copenhagen University
vre, Denmark. Fax: +45 3647
rights reserved.and the 3′UTR (Honda et al., 1996; Reynolds et al., 1995; Song et al.,
2006), to produce a single polyprotein of ~3000 amino acids
(Tsukiyama-Kohara et al., 1992; Wang et al., 1993). The polyprotein
precursor is cleaved co- and post- translationally by cellular signal
peptidases and viral proteases into at least 10 proteins, including
structural proteins Core, E1, and E2 at the N-terminus, followed by a
small protein p7 and the nonstructural (NS) proteins NS2, NS3,
NS4A, NS4B, NS5A, and NS5B (Moradpour et al., 2007).
HCV has been classiﬁed into seven major genotypes and numer-
ous subtypes, differing in approximately 31–33% and 20–25% of
their genome sequence, respectively (Murphy et al., 2007; Simmonds
et al., 2005). HCV genotype-speciﬁc responses were found in clinical
interferon-alpha (IFN-α)-based therapy (Zeuzem, 2008), and in
vitro regarding newly developed inhibitors (Gottwein et al., 2011;
Scheel et al., 2011b) and neutralizing antibodies (Gottwein et al.,
2009; Jensen et al., 2008; Prentoe et al., 2011; Scheel et al., 2008).
Most of the previously developed JFH1-based HCV genotypes 1–7
speciﬁc Core-NS2 recombinants required adaptive mutations for efﬁ-
cient growth in Huh7.5 cells (Gottwein et al., 2007, 2009; Jensen et
al., 2008; Scheel et al., 2008, 2011a), which indicates that genotype-
speciﬁc interactions exist between Core-NS2 and other regions of
the HCV genome or between HCV RNA and cellular proteins. Further,
using JFH1-based HCV culture systems, our research group recently
demonstrated that the E2 hypervariable region 1 (Prentoe et al.,
2011) and NS5A (Scheel et al., 2011b) apparently functioned in a
genotype-speciﬁc manner in production of infectious HCV particles.
We have recently demonstrated that JFH1-based HCV recombinants
with genotypes 1–6 speciﬁc 5′UTR-NS2 were fully functional with
Fig. 1. Structure and sequences of the HCV 5′UTR. A) Secondary structure of the 5′UTR of HCV genotype 1a strain H77 as predicted by Honda et al. (Honda et al., 1999a). The
nucleotides at positions with heterogeneity among HCV genotype isolates shown in panel B are in red; those with deletions are underlined. Arrows indicate the positions of inser-
tion nucleotides of HCV genotype 6a. The microRNAmiR-122 binding site 1 and 2 (S1 and S2) and their upstream nucleotides involved in this binding are boxed (Jopling et al., 2005,
2008; Machlin et al., 2011). The start codon AUG is highlighted. B) The 5′UTR sequences of HCV prototype strains of different genotypes. The entire 5′UTR sequence of genotypes 1a,
1b, 2a, 2b, 3a, 4a, 5a and 6a (Gottwein et al., 2010; Kato et al., 2001; Kolykhalov et al., 1997; Li et al., 2011; Sakai et al., 2007) are aligned and numbered according to the reference 1a
strain H77 (GenBank accession number AF009606) (Kolykhalov et al., 1997). A dot indicates that the nucleotide is identical to H77; a dash indicates a gap. MicroRNA miR-122 bind-
ing sequences are indicated. In A) and B): Domains I, II and III are highlighted in colors.
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the 5′UTR has no genotype-speciﬁc interaction with NS3-3′UTR.
However, whether the 5′UTR has genotype-speciﬁc functions or is in-
volved in genotype-speciﬁc interactions with the Core-NS2 region
could not be studied with these systems. We aimed at investigating
this issue by developing novel JFH1-based recombinants with 5′UTR
of different HCV genotypes.
Although the 5′UTR is highly conserved among HCV genotypes,
the most distantly related isolates were found to differ in up to
~10% of their sequence; variable regions could be identiﬁed primarily
in domains I, II and III (Bukh et al., 1992; Han et al., 1991; Li et al.,
2011). A number of well-deﬁned genotype-speciﬁc polymorphisms
have been widely used for HCV genotyping (Ross et al., 2000;
Simmonds et al., 2005). In addition, the 5′UTR was shown to be in-
volved in long-range RNA–RNA interactions with coding sequences
of Core (Honda et al., 1999b; Kim et al., 2003) and NS5B SL3.2 (also
as SL9266) (Romero-Lopez and Berzal-Herranz, 2009) in in vitro
translation and binding assays. Binding assays showed that interac-
tions also existed between the 5′UTR domains (Lafuente et al.,
2002). The 5′UTR was suggested to interact with the NS3 helicase,
NS5A and NS5B in a genotype-speciﬁc manner, during positive-
strand RNA synthesis using subgenomic 1b (strain Con1) and 2a
(JFH1) replicon systems (Binder et al., 2007). However, it is unknown
whether the heterogeneities in the 5′UTRs mediate genotype-speciﬁc
functions important for production of infectious HCV particles.
HCV infects approximately 180 million people worldwide, and
around 80% of infected patients develop chronic hepatitis with high
risk of developing liver cirrhosis and hepatocellular carcinoma (Manns
et al., 2007). No vaccine is available for hepatitis C. Vigorous efforts
are ongoing to search for potential new therapeutics, including 5′UTR-
targeting drugs (Lanford et al., 2010; Parsons et al., 2009; Paulsen
et al., 2010). Silencing of miR-122 by antisense locked nucleic acids
(LNA) SPC3649was found to be a promising approach, as it was demon-
strated to suppress HCV genotype 1 chronic infection in chimpanzees
(Lanford et al., 2010) and to inhibit the infection of HCV genotypes
1–6 5′UTR-NS2 recombinants in vitro (Li et al., 2011). Nevertheless,
IFN-α2 and ribavirin have long been the only approved therapy for
HCV patients (Zeuzem, 2008), although recently the protease inhibitors
Telaprevir and Boceprevir were licensed for use in combination with
pegylated interferon and Ribavirin for the treatment of genotype 1
chronic hepatitis C patients. Combination therapy with IFN-α2 and
ribavirin overall cures 40–80% of chronically infected individuals
completing treatment (Alter and Seeff, 2000; Poynard et al., 2003).
The outcome of this combination therapy is highly dependent on the
HCV genotype; patients infected with HCV genotypes 2 and 3 show
higher sustained viral response rates than those infected with geno-
types 1 and 4 (Pawlotsky, 2003; Zeuzem, 2004). The mechanisms of
HCV resistance to IFN-based treatment are poorly understood. Although
various genome regions, such as E2 and NS5A, were thought to play a
role in IFN resistance, the observations are still controversial [reviewed
in (Gottwein and Bukh, 2008)]. Regarding the role of the 5′UTR in re-
sponse to IFN treatment, differing results have also been reported
(Koev et al., 2002; Lu et al., 1999; Soler et al., 2002; Takeda et al.,
2004). Thus, studies of the genetic basis that confers resistance to IFN
for various HCV genotypes are highly relevant.
Results
Apparent lack of genotype-speciﬁc interaction between the 5′UTR and
other HCV genome regions in virus production in vitro
We and others previously developed JFH1-based HCV genotypes
1–7 Core-NS2 recombinants, in which the Core-NS2 region was from
different genotypes 1–7 strains, and the 5′UTR and NS3-3′UTR were
from genotype 2a strain JFH1 (Gottwein et al., 2007, 2009; Jensen et
al., 2008; Lindenbach et al., 2005; Scheel et al., 2008, 2011a). TheHCV5′UTRwas reported to be involved in long-range RNA–RNA interac-
tions and RNA–protein interactions important for HCV RNA replication
and translation [reviewed in (Shi and Lai, 2006)]. To study whether
these potential functional interactions were genotype-speciﬁc and
inﬂuenced virus production, here we developed (i) JFH1-based HCV ge-
notypes 1–7 Core-NS2 recombinants with highly diverse 5′UTR of geno-
types 1a and 3a, and (ii) HCV 2a Core-NS2 recombinants (J6/JFH1)
(Lindenbach et al., 2005) with 5′UTR of genotypes 1–6 (see below). By
determining virus spread, culture supernatant HCV infectivity titers
and supernatant HCV RNA titers of these recombinants in transfected
and infected Huh7.5 cells, we concluded that the 5′UTR did not appear
to have genotype-speciﬁc functions and interactions with other HCV
genome regions important for virus production in Huh7.5 cells.
1) JFH1-basedHCV genotypes 1–7Core-NS2 recombinantswith heterologous
5′UTR of genotypes 1a and 3a strains were fully functional in vitro
We previously determined the 5′UTR sequence of HCV prototype
genotypes 1b (strain J4), 2a (J6), 2b (J8), 3a (S52), 4a (ED43), 5a
(SA13) and 6a (HK6a) using experimentally infected chimpanzee
plasma pools (Bukh et al., 2010; Gottwein et al., 2010; Li et al.,
2011). An alignment of these HCV 5′UTR sequences and the genotype
1a 5′UTR of reference strain H77 (GenBank accession number
AF009606) (Kolykhalov et al., 1997) (Fig. 1B) showed that the 3a
5′UTR differed from the 1a 5′UTR by 27 nucleotides and 2 single nucle-
otide deletions. Of these differences, 13 nucleotides and 1 deletionwere
found to be unique to the 3a 5′UTR. Thus, the 3a 5′UTR represents a
highly deviated 5′UTR among HCV genotypes. In addition, the 5′UTR
of HCV genotype 3 was relatively conserved among subtype isolates
(HCV databases), and the 5′UTR of 3a strain S52 should therefore be
representative of most genotype 3 isolates. To study whether 1a
and 3a-speciﬁc nucleotides mediated genotype-speciﬁc functions or in-
teractions with other HCV genome regions, such as the Core-NS2 re-
gion, we generated novel JFH1-based HCV genotypes 1–7 Core-NS2
recombinants with heterotypic 1a or 3a 5′UTR, based on previously de-
veloped Core-NS2 recombinants that all contain the genotype 2a (strain
JFH1) 5′UTR (Fig. 2A) (Gottwein et al., 2007, 2009; Jensen et al., 2008;
Lindenbach et al., 2005; Scheel et al., 2008). The RNA transcripts of
these recombinants were transfected into Huh7.5 cells; corresponding
recombinants with JFH1 5′UTR or with genotype-speciﬁc 5′UTR
(referred to as 5′UTR-NS2 recombinants) (Li et al., 2011) (Fig. 2A)
were included in parallel for comparison. HCV positive cells were
detected by immunostaining for HCV NS5A and estimated as percent-
age of infected cells to monitor virus spread. All JFH1-based HCV geno-
types 1–7 Core-NS2 recombinants spread efﬁciently in transfected
cultures and reached peak infection (estimated by anti-NS5A staining
with≥80% infected cells)within 5 to 8 days after transfection, irrespec-
tive of the genotype strain of the 5′UTR. The peak HCV infectivity titers
of culture supernatants of the Core-NS2 recombinant viruses with
heterotypic 5′UTR of 1a or 3a were similar to those of corresponding
viruses with JFH1 5′UTR or with genotype-speciﬁc 5′UTR (Fig. 2B).
Next, we performed comparative growth kinetics studies for
genotypes 2a and 3a Core-NS2 recombinant viruses with different
5′UTRs.We infectednaïveHuh7.5 cellswith transfection-derived virus-
es at amultiplicity of infection (MOI) of 0.003 focus forming units (FFU)
per cell. The results showed that the viral growth kinetics and peak
viral infectivity titers of the 2a Core-NS2 recombinant (J6/JFH1)
viruses with heterotypic 1a or 3a 5′UTR were comparable to those
of corresponding viruses with JFH1 5′UTR or with genotype-speciﬁc 5′
UTR (Fig. 2C). The HCV RNA titers were also similar at the corresponding
time points with peak titers reaching 108.0–108.2 IU/mL. Likewise, the 3a
Core-NS2 recombinant viruses with different 5′UTRs were comparable
with respect to growth kinetics, peak HCV infectivity titers (Fig. 2C)
and HCV RNA titers [108.4 international unit (IU)/mL]. Therefore, ex-
changing the 5′UTR from original 2a (JFH1) 5′UTR to 1a or 3a 5′UTR
did not affect viability of JFH1-based HCV genotypes 1–7 Core-NS2
recombinants; the nucleotide polymorphisms between the 5′UTR of
Fig. 2. JFH1-based genotypes 1–7 Core-NS2 recombinants with 5′UTR of genotypes 1a and 3a were fully viable in Huh7.5 cells. A) Schematic diagram of JFH1-based HCV recombinants.
Using previously developed JFH1-based HCV genotypes 1–7 Core-NS2 recombinants, which contain JFH1 5′UTR and NS3-3′UTR (in blue) (Gottwein et al., 2007, 2009; Jensen et al., 2008;
Lindenbach et al., 2005; Scheel et al., 2008), here we developed corresponding recombinants with heterotypic 5′UTR of genotypes 1a (strain H77) (in red) and 3a (S52) (in purple). The
3a 5′UTR used here has G at the 5′-terminus, different from the prototype 3a strain S52 from the chimpanzee plasma pool, which has A at the 5′-terminus (Fig. 1B) (Gottwein et al., 2010;
Li et al., 2011). Previously developed JFH1-based HCV genotypes 1–6 Core-NS2 recombinants with genotype-speciﬁc 5′UTR (referred to as 5′UTR-NS2 recombinants) (Li et al., 2011)
were included for comparison. B) Transfection of Huh7.5 cells with RNA transcripts from indicated recombinants. In RNA transfection, the transfection complexes were incubated
with cells in DMEM medium supplemented with 10% FBS for ~16 h before subculture, and HCV infection and spread were detected by immunostaining for HCV NS5A (see Materials
and methods). HCV infectivity titer of culture supernatants collected at peak infection (estimated by anti-NS5A staining, with ≥80% infected cells) was determined by focus forming
units (FFU) assay and presented as mean±standard error of the mean (SEM) of triplicate infections (see Materials and methods for details). *, the recombinant was from a separate
transfection experiment. C) Comparative growth kinetics study. Naïve Huh7.5 cells were infected with transfection-derived 2a and 3a Core-NS2 recombinants with different 5′UTRs
at MOI of 0.003 FFU/cell, cells were split every 2–3 days, and culture supernatant infectivity titers were determined (supernatant was not collected at day 1) and shown as mean
±SEM of triplicate infections.
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tion or interactions important for production of infectious HCV in vitro.
To demonstrate whether exchange of the 2a (JFH1) 5′UTR with 1a
or 3a 5′UTR required additional adaptive mutations in the genome
other than those required for the original Core-NS2 genotype recom-
binant viruses, we selected the 2a, 3a and 5a Core-NS2 recombinants
with 5′UTR of 1a and 3a for further analysis. Recombinant viruses de-
rived from peak infection supernatant of ﬁrst passage (Fig. 2C and not
shown) required no additional mutations in the ORF and the 3′UTR,
however, the 5′-terminal G of the 5′UTR was in all cases changed to
A (Table 1), in line with previous observations for 5′UTR-NS2 recom-
binants (Li et al., 2011). The 5′-terminal nucleotide of prototype 3a
strain S52 is A (Fig. 1) (Gottwein et al., 2010), however we used G
in all recombinants with the 3a 5′UTR. Thus the G to A change in
the 3a 5′UTR of these recombinants might have represented rever-
sions to the original 3a sequence.2) J6/JFH1 recombinants with heterologous 5′UTR of genotypes 1–6 were
fully functional in vitro
To study whether the 5′UTR of HCV genotypes 1b, 2b, 4a, 5a and 6a
mediated genotype-speciﬁc interactions important for production of
infectious virus particles, we constructed J6/JFH1 recombinants with
5′UTR of these genotypes (Fig. 3A). Together with the previously devel-
oped 2a 5′UTR-NS2 recombinant (Li et al., 2011) and the J6/JFH1 recom-
binantswith 5′UTR of genotypes 1a and 3a (Fig. 2A),we thus completed
a panel of J6/JFH1 recombinants with 5′UTR of HCV genotypes 1–6
(Fig. 3A). This enabled us to perform functional analysis of the 5′UTR
of HCV genotypes 1a (strain H77), 1b (J4), 2a (J6), 2b (J8), 3a (S52),
4a (ED43), 5a (SA13) and 6a (HK6a) in an identical Core-3′UTR
genetic background. Transfection of Huh7.5 cells with RNA transcripts
of these recombinants showed that all J6/JFH1 recombinants with
5′UTR of genotypes 1–6 reached peak infection at day 3 post-
transfection, and produced infectious virus particles with similar
Table 1
Characterization of JFH1-based HCV genotypes 2a, 3a and 5a Core-NS2 recombinants with 1a or 3a-speciﬁc 5′UTR.
JFH1-based HCV
recombinants
Transfection First Passage Mutation
5′UTR
(strain)
Core-NS2
(strain)
Day of ≥80%
infected cells
Peak infectivity titer
(Log10(FFU/mL))
MOI Day of ≥80%
infected cells
Peak infectivity titer
(Log10(FFU/mL))
5′UTR⁎ Core-NS5B# 3′UTR¤
1a (H77) 2a (J6) 5 4.1 0.003 7 4.7 G1A None NCC
3a (S52) 2a (J6) 8 4.2 0.003 7 4.3 G1A None NCC
1a (H77) 3a (S52) 8 4.1 0.003 7 4.5 G1A None NCC
3a (S52) 3a (S52) 8 4.5 0.003 7 4.5 G1A None NCC
1a (H77) 5a (SA13) 3 4.5 n.d. 7 4.8 G1A None NCC
3a (S52) 5a (SA13) 8 4.5 0.015 11 4.7 G1A None NCC
The 2a, 3a and 5a Core-NS2 recombinant viruses with 5′UTR of genotypes 1a and 3a derived from infection supernatant taken at peak infection (estimated with≥80% infected cells)
were subjected to sequence analysis of the entire genome, including the 5′ and 3′UTRs. MOI, multiplicity of infection. n.d., MOI was not determined; 1 ml transfection supernatant
was used for infection. *, the entire 5′UTR sequences were determined by rapid ampliﬁcation of 5′ complementary DNA ends (5′RACE) procedure on HCV positive-strand RNA
extracted from culture supernatant, and the second round PCR products were directly sequenced. Nucleotide (nt) G was used at 5′ terminus of 3a 5′UTR (prototype 3a strain
S52 has A at 5′ terminus (Fig. 1B) (15, 34)). ¤, the 3′UTR sequences were determined by 5′RACE on HCV negative-strand RNA extracted from infected cells, and the second
round PCR products were cloned for sequence analysis. No consensus change (NCC) was observed in the 3′UTR, however, poly(U/UC) tracts of different length were identiﬁed,
without any particular pattern for a particular recombinant. #, in other independent experiment(s), mutations were identiﬁed in recombinant J6/JFH1 with 1a 5′UTR [in the
2nd experiment: NS5A, T6352A(F2004Y) and A6761A/G; in the 3rd experiment: E2, A1671G(T444A) and NS3, T5252C/t] and 5a Core-NS2 recombinant with 1a 5′UTR [NS2,
T3334G(L998R) and NS5B, G8303T(M2654I)]. Although these genomes replicated efﬁciently, it is possible that these mutations represent putative adaptive mutations, but they
could also be mutations resulting from errors introduced during RT-PCR.
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pernatant collected at peak infection was passaged to naïve Huh7.5
cells with MOI of 0.003 FFU/cell. In these cultures, all J6/JFH1 viruses
with 5′UTR of genotypes 1–6 spread comparably with increasing
and equivalent HCV infectivity titers (Fig. 3B) and HCV RNA titers
(reaching 107.7–107.8 IU/mL) during days 3–9. Therefore, the 5′UTR
of HCV genotypes 1–6 did not appear to have genotype-speciﬁc func-
tion or interactions with other HCV genome regions being of impor-
tance in production of infectious HCV in vitro.
Sequence analysis of the 5′UTR of the passaged viruses collected at
day 7 post infection (Fig. 3B) revealed that the 5′-terminal G was
changed to A in the 5′UTR of genotypes 1a, 1b, 2b, 3a and 6a; the
5′-terminal A of the 5′UTR of 2a, 4a and 5a was maintained, however,Fig. 3. J6/JFH1 recombinants with 5′UTR of HCV genotypes 1–6 were fully functional in
Huh7.5 cells. A) Schematic diagram of HCV recombinants. The 5′UTR of HCV genotypes
1–6 was engineered into the corresponding region of the 2a recombinant J6/JFH1, which
contains 2a J6 Core-NS2 and JFH1 NS3-3′UTR (Lindenbach et al., 2005). B) Comparative
growth kinetics study. Naïve Huh7.5 cells were infected with transfection-derived 2a
Core-NS2 recombinants with 5′UTR of genotypes 1–6 (MOI=0.003 FFU/cell). Culture su-
pernatant infectivity titers (mean±SEM of triplicate infections) are shown.the G inserted immediately upstream of the 5′-terminal A for enhanc-
ing in vitro transcription was deleted. The change at the 5′-terminus is
consistent with our observations for Core-NS2 recombinants with
5′UTR of 1a or 3a (Table 1) and with our previous observations
for 5′UTR-NS2 recombinants (Li et al., 2011).
Apparent lack of genotype-speciﬁc interaction of HCV 5′UTR domains I, II
and III with inﬂuence on virus production in vitro
The nucleotide heterogeneities found in the 5′UTR are primarily
located in domains I, II and III [Fig. 1B and (Bukh et al., 1992)], and
we therefore investigated whether these heterogeneous nucleotides
mediate genotype-speciﬁc interactions among 5′UTR domains. We
constructed and characterized (i) HCV 1a 5′UTR-NS2 recombinants
with 5′UTR domain I of genotypes 1–6, and (ii) J6/JFH1 recombinants
with heterotypic chimeric 5′UTR, in which 5′UTR domains I, II or III of
1a and 3a were exchanged (see below). By characterization of these
recombinants in transfection and infection of Huh7.5 cells, we con-
cluded that the interactions, if any, among HCV 5′UTR domains I, II
and III did not appear to be genotype-speciﬁc and essential for HCV
production in vitro.
1) JFH1-based HCV 1a 5′UTR-NS2 recombinants with 5′UTR domain I
sequences of genotypes 1–6 were fully functional in Huh7.5 cells
The 5′UTR domain I (nucleotides 1–43) is essential for HCV RNA
replication (Friebe et al., 2001). This domain contains SLI that is im-
portant for in vitro HCV RNA replication (Luo et al., 2003) and virus
production (Li et al., 2011). A cluster of nucleotide heterogeneities
was found in domain I of the 5′UTR, primarily within SLI (nucleotides
5–20); genotypes 2a (strain J6), 3a (S52), 4a (ED43), 5a (SA13) and
6a (HK6a) contain deletions in this region (Fig. 1B). We thus studied
whether these heterogeneous nucleotides mediate genotype-speciﬁc
functions or interactions in virus production. We developed 1a (strain
H77) 5′UTR-NS2 recombinants with heterotypic 5′UTR domain I of
genotypes 1–6 (Fig. 4A), using the previously developed 1a 5′UTR-
NS2 recombinant (Li et al., 2011). RNA transfection of Huh7.5 cells
showed that these recombinants spread efﬁciently in transfected cul-
tures and produced infectious virus particles with peak HCV infectiv-
ity titers (103.5–103.8 FFU/mL) similar to 1a 5′UTR-NS2 recombinant
virus (103.5 FFU/mL). Viruses in supernatant from peak HCV infection
were further characterized by comparative growth kinetics studies
by infection of naïve Huh7.5 cells with identical virus doses
(MOI=0.003 FFU/cell) (Figs. 4B and C). The results showed that the
HCV growth kinetics monitored by supernatant HCV infectivity titers
(Figs. 4B and C) and peak HCV RNA titers (108.1–108.5 IU/mL) of these
Fig. 4. JFH1-based 1a 5′UTR-NS2 recombinants with HCV genotypes 1–6 speciﬁc do-
main I sequences were fully viable in Huh7.5 cells. A) Schematic diagram of 1a (strain
H77) 5′UTR-NS2 recombinants (Li et al., 2011) with 5′UTR domain I (nucleotides 1–43)
of HCV genotypes 1b, 2a, 2b, 3a, 4a, 5a and 6a. B and C) Comparative growth kinetics
study. Naïve Huh7.5 cells were infected with transfection-derived 1a 5′UTR-NS2
recombinants with 5′UTR domain I of HCV genotypes 1–6 (MOI=0.003 FFU/cell). Cul-
ture supernatant HCV infectivity titers (mean±SEM of triplicate infections) are shown.
*, indicates that the HCV infectivity titer was below the detection limit of 2.3 Log10
(FFU/mL), as shown by a broken line. In a separate experiment, the peak HCV infectiv-
ity titer of the 1a 5′UTR-NS2 recombinant virus with 5′UTR domain I of 6a were com-
parable to that of the virus with wild-type 1a 5′UTR (data not shown).
Fig. 5. Fully functional JFH1-based HCV 2a Core-NS2 recombinants with heterotypic 1a/
3a or 3a/1a chimeric 5′UTR domains. A) Schematic diagram of 2a (strain J6) Core-NS2
recombinants with 1a/3a chimeric 5′UTRs. The domains I, II or III of the 5′UTR of geno-
types 1a and 3a were exchanged and engineered into the 2a Core-NS2 recombinant.
The 2a Core-NS2 recombinants with wild-type 5′UTR of genotypes 1a and 3a were in-
cluded for comparison. B) Comparative growth kinetics study. Naïve Huh7.5 cells were
infected with transfection-derived 2a Core-NS2 recombinants with heterotypic chime-
ric 5′UTRs (MOI=0.003 FFU/cell). Culture supernatant HCV infectivity titers are shown
(mean±SEM of triplicate infections).
227Y.-P. Li et al. / Virology 421 (2011) 222–234heterotypic 5′UTR domain I viruses were comparable to those of the
1a 5′UTR-NS2 recombinant virus.
Sequence analysis of the 5′UTR of ﬁrst passage virus revealed that
the heterotypic 5′UTR domain I was maintained in all viruses. How-
ever, the 5′-terminal G of genotypes 1b, 3a and 6a was changed to
A, while the 5′-terminal G of genotype 2b was changed to AC (in 3
out of 3 clones analyzed). The 5′-terminal A of 2a, 4a and 5a domain
I was maintained, however, the G inserted immediately upstream of
the 5′-terminal A for enhancing in vitro transcription was deleted.
Taken together, the 5′UTR domain I of genotypes 1b, 2a, 2b, 3a, 4a,
5a and 6a had no genotype-speciﬁc functions or interactions with
other HCV genome regions essential for production of infectious
HCV in Huh7.5 cells.
2) HCV recombinant J6/JFH1 with heterotypic chimeric genotype 1a/3a
or 3a/1a 5′UTR domains I, II and III were fully viable in Huh7.5 cells
Since 5′UTR nucleotide heterogeneities are primarily found in do-
mains I, II and III (Fig. 1B) (Bukh et al., 1992), we further investigated
whether these nucleotides mediate genotype-speciﬁc interactionsamong 5′UTRdomains. The 3a 5′UTR varied themost amongHCV geno-
types 1–6 strains, differing from the 1a 5′UTR by 7, 4 and 15 nucleotides
in domains I, II and III, respectively. In addition, the 3a 5′UTR domain I
had two single nucleotide deletions (Fig. 1B). We thus generated J6/
JFH1 recombinants with heterotypic 5′UTR with 1a/3a or 3a/1a combi-
nation of domains I, II and III (Fig. 5A). Transfection of Huh7.5 cells with
RNA transcripts from these recombinants showed that all six J6/JFH1
recombinants with chimeric 1a/3a or 3a/1a 5′UTRs spread efﬁciently
in the culture and produced infectious viruses with HCV infectivity
titers comparable to corresponding viruses with the complete 1a or 3a
5′UTR (~104.5 FFU/mL). Viruses in culture supernatants derived from
the peak of HCV infection were further characterized by comparative
growth kinetics studies. In naïve Huh7.5 cells infected with identical
MOI (0.003 FFU/cell), the HCV growth kinetics determined by superna-
tant HCV infectivity titers (Fig. 5B), as well as the peak HCV RNA titers
(107.2–107.6 IU/mL) of the viruses with chimeric 5′UTR were similar to
those of corresponding viruses with complete 1a or 3a 5′UTR. Sequence
analysis of the entire 5′UTR of the viruses recovered at day 7 post-
infection (Fig. 5B) revealed that the chimeric 5′UTR domains were
maintained. However, the 5′-terminal G was in all cases changed to A,
in line with observations with other JFH1-based recombinants
[Table 1 and (Li et al., 2011)]. Hence, the heterogeneities in domains I,
II and III of the 5′UTR of genotypes 1a and 3a did not appear to mediate
genotype-speciﬁc functions or interactions among 5′UTR domains es-
sential for production of infectious HCV in Huh7.5 cells.
Adenine at the 5′-terminus of the HCV genome is required for JFH1-based
recombinants in vitro
Since all JFH1-based HCV recombinant viruses recovered from cul-
tures, either in the present study (Table 1 and above) or in our previous
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had A at the 5′-terminus, we speculated that the A at the 5′-terminus
is required for efﬁcient growth of JFH1-based HCV recombinants in
Huh7.5 cells, irrespective of the genotype strain of the 5′UTR. We
thus mutated the 5′-terminal G of 1a (strain H77) 5′UTR-NS2 recom-
binant to A, U and C, designated 1a-G1A, 1a-G1U and 1a-G1C, respec-
tively (Fig. 6A) and the 5′-terminal A of 2a 5′UTR-NS2 recombinant
into G, U and C, designated 2a-A1G, 2a-A1U and 2a-A1C, respectively
(Fig. 6B). In addition, we deleted the 5′-terminal A of the 2a 5′UTR-
NS2 recombinant to generate 2a-A1Δ (Fig. 6B). To study the authen-
ticity of the RNA transcripts used for transfection, an aliquot of the in
vitro-transcribed RNA transcripts was subjected to 5′RACE proce-
dures to determine the entire 5′UTR sequence, while another aliquot
of the RNA transcripts was used for transfection of Huh7.5 cells. For
all constructs except 2a-A1C the correct sequences of the RNA tran-
scripts were identiﬁed (Figs. 6A and B). However, in the clones with
C at the 5′-terminus additional cytidines were identiﬁed in the RNA
transcripts (Figs. 6A and B). In RNA transfection of Huh7.5 cells, all
5′-terminal nucleotide mutants spread efﬁciently and produced
HCV with peak viral infectivity titers comparable to corresponding
virus with the wild-type 5′-terminal nucleotide (Figs. 6A and B). The
transfection-derived recombinant virus could be passaged to naïve
Huh7.5 cells. Sequence analysis of the 5′UTR of such ﬁrst passage virus-
es revealed that Awas invariably identiﬁed at the 5′-terminus of 1a and
2a 5′UTR-NS2 recombinant viruses, regardless of whether A, G, U or C
were present at the 5′-terminus of the RNA transcripts (Figs. 6A and
B). In a separate independent experiment, in which RNA transcripts of
these nine recombinants were not conﬁrmed by 5′RACE procedure, all
the recovered viruses also contained A at 5′-terminus (data not
shown). Hence, A at the 5′-terminus is apparently required for efﬁcient
growth of the JFH1-based recombinants in Huh7.5 cells.
In ﬁrst passage-recovered viruses of 2a-A1C, 2a-A1U or 2a-A1Δ,
insertions of one or two cytidines were observed in 5′-proximal se-
quences between nucleotide 1 and 5 of several clones (Fig. 6B and
data not shown from the independent experiment, where the RNA
transcripts were not sequenced). These insertions might have
resulted from insertions introduced during synthesis of the RNA tran-
scripts (Fig. 6B). The cytidines at position 2 and 3 of the 5′UTR se-
quences were believed to be involved in binding to the miR-122
molecules that bind to miR-122 binding site 1 (Fig. 1) (Machlin et
al., 2011). We recently demonstrated that introducing mutations in
miR-122 binding site 1 could confer viral resistance to the inhibitory
effect of SPC3649-mediated miR-122 antagonism (Li et al., 2011).
Thus, we constructed a 2a 5′UTR-NS2 recombinant with insertion of
two cytidines (2a-Ins2C) to test its sensitivity to miR-122 silencing.
In RNA transfection of Huh7.5 cells, the viability of this recombinant
was comparable to that of the wild-type 5′UTR 2a recombinant
(data not shown). However, in ﬁrst passage-recovered virus only
one C was maintained (2a-Ins1C). The infection of the 2a-Ins1C
virus in SPC3649-transfected Huh7.5 cells was efﬁciently suppressed
in two experiments, to the level of inhibition observed for the wild-
type 5′UTR 2a recombinant virus, whereas a resistant mutant Cell-
U3 (Li et al., 2011) was not inhibited by the treatment (Figs. 7A and
B). Thus, the data indicated that insertion of one C at the 5′-proximal
sequence (between nucleotides 1 and 5) did not confer viral resis-
tance to the inhibitory effect of miR-122 antagonism.
The J6/JFH1 recombinants with 5′UTR of genotypes 1–6 responded
similarly to interferon-α2b
Although it has been suggested that the 5′UTR could be a target of
IFN (Dash et al., 2005; Hazari et al., 2005) and that the IRES might
contribute to IFN resistance (Koev et al., 2002), no suitable culture
systems were available to test the role of the HCV 5′UTR in response
to IFN in a genotype-speciﬁc manner. Development of viable J6/JFH1
recombinants with 5′UTR of HCV genotypes 1–6 (Fig. 8A) provides aunique opportunity to study the 5′UTR of HCV major genotypes in
viral responses to IFN treatment. We infected Huh7.5 cells with ﬁrst
passage recombinant viruses, and then treated with IFN-α2b. Median
effective concentration (EC50) was determined to be 0.2–1.2 IU/mL
for J6/JFH1 recombinant with JFH1 5′UTR (Gottwein et al., 2011;
Scheel et al., 2011b). Treatment of infected Huh7.5 cells with 40 IU/
mL and 60 IU/mL in two independent experiments showed that
virus infections were suppressed, with ~20% infection relative to the
respective infection in mock-treated controls, while treatment with
0.4 IU/mL and 0.6 IU/mL showed 60–80% infection. The IFN doses
used were previously shown not to have a cytotoxic effect (Gottwein
et al., 2009; Scheel et al., 2011b). All the recombinant viruses with dif-
ferent 5′UTRs responded to IFN treatment in a dose dependent man-
ner, and no major difference was observed between the viruses with
different 5′UTRs (Figs. 8B and C). Thus, the 5′UTR of HCV genotypes
1–6 did not appear to confer a genotype-speciﬁc response to IFN-
α2b treatment in Huh7.5 cells.
Discussion
The functional importance and the conserved nature of the HCV 5′
UTR attract great interest in exploring this genome region as a thera-
peutic target against HCV infection. However, current knowledge on
the role of the 5′UTR of HCV was mainly gained from the in vitro
HCV replicon systems and translation assays (Shi and Lai, 2006),
which did not permit studies of the complete HCV life cycle. Also, it
has not been possible to study the 5′UTR of different HCV genotypes,
primarily due to the unavailability of entire 5′UTR sequences and
suitable culture systems. In this study, we for the ﬁrst time demon-
strated that the 5′UTR of HCV genotypes 1–6 functioned in a non-
genotype-speciﬁc manner in production of infectious HCV particles
in vitro, by developing and characterizing a large panel of novel viable
JFH1-based recombinants. We also demonstrated that the HCV 5′UTR
of genotypes 1–6 had no genotype-speciﬁc functions or interactions
with other genome regions, with special emphasis on the Core-NS2
sequences included in JFH1-based recombinants. We also found that
despite signiﬁcant sequence heterogeneity, there are apparently no
genotype-speciﬁc interactions among the 5′UTR internal domains of
importance for the complete HCV life cycle in vitro. We further dem-
onstrated by reverse genetic studies that A at the 5′-terminus was re-
quired for JFH1-based HCV recombinants in Huh7.5 cells. The
developed HCV genotypes 1–7 Core-NS2 recombinants (Fig. 2A), as
well as J6/JFH1 recombinants (Fig. 3A), with heterotypic 5′UTRs pro-
vided optimal platforms for studying the interactions that the 5′UTR
may be involved with in a genotype-speciﬁc manner. These systems
could also facilitate the development of novel 5′UTR-based antivirals
against HCV. The HCV recombinants with chimeric 5′UTR domain(s)
(Figs. 4A and 5A) further enable the analysis of interactions among
5′UTR domains or future screening of 5′UTR domain-speciﬁc drugs,
for example, domain II-targeting benzimidazole derivatives (Parsons
et al., 2009; Paulsen et al., 2010).
Previous studies showed that exchange of the genotype 2a (JFH1)
5′UTR with 1a (H77) or 1b (Con1) 5′UTR reduced the replication of a
JFH1 subgenomic replicon with ﬁreﬂy luciferase reporter, while ex-
change with the 2a (J6) 5′UTR did not affect replication (Binder
et al., 2007). Thus, the data suggested a genotype-speciﬁc role of the
5′UTR in HCV RNA synthesis. Here we demonstrated that genotypes
1–7 Core-NS2 recombinants with heterotypic 5′UTR of genotypes 1a
and 3a were fully viable in Huh7.5 cells, with viral infectivity titers
similar to corresponding viruses with JFH1 5′UTR (Gottwein et al.,
2007, 2009; Jensen et al., 2008; Lindenbach et al., 2005; Scheel et
al., 2008), or with matching genotype-speciﬁc 5′UTR (Li et al., 2011)
(Figs. 2A and B). Further, the viability of J6/JFH1 recombinants with
5′UTR of HCV genotypes 1–6 was similar (Fig. 3). Thus, our data indi-
cated that the 5′UTR had no genotype-speciﬁc functions or interac-
tions that were critical for efﬁcient production of infectious HCV in
Fig. 6.Mutagenesis studies of the 5′-terminal nucleotide of JFH1-basedHCV recombinants inHuh7.5 cells. The 5′-terminal nucleotide of 1a (A) and 2a (B) 5′UTR-NS2 recombinant viruses
were mutated to other nucleotides as indicated. In addition, the 5′-terminal A of the 2a 5′UTR-NS2 recombinant was deleted (2a-A1Δ). RNA transcripts of the recombinants were gen-
erated using T7 RNA polymerase and divided into two aliquots. The HCV 5′UTR sequence of the RNA transcripts was analyzed by 5′RACE procedures using one aliquot of the RNA tran-
scripts, and the 5′-terminal sequences are indicated (direct consensus sequencing or, if required, clonal analysis presented as the number of clones with indicated sequence/total clones
analyzed); no changeswere observed in the remainder of the 5′UTR. The other aliquot of the RNA transcriptswas used for transfection of naïve Huh7.5 cells. HCV infectivity titers of trans-
fection culture supernatants are shown (mean±SEM of triplicate infections). *, indicates that the infectivity titer was below detection limit of 2.3 log10(FFU/mL), as shown by a broken
line. Transfection culture supernatants collected at day 7werepassaged to naïveHuh7.5 cells and the 5′UTR sequence of the recovered viruseswere analyzedby5′RACEprocedures (direct
consensus sequencing or, if required, clonal analysis); no changes were observed in the remainder of the 5′UTR. Throughout nucleotides identical to the wild-type sequence are in green.
#, only one clone with full-length 5′UTR was obtained; however the direct sequencing of the 5′RACE amplicons clearly indicated the presence of ACCCG and ACCCCG.
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Fig. 8. HCV2a recombinant J6/JFH1with 5′UTR ofHCV genotypes 1–6 responded similarly
to interferon (IFN)-α2b treatment in Huh7.5 cells. A) Schematic diagram of JFH1-based 2a
Core-NS2 recombinant viruses with 5′UTR of HCV genotypes 1–6. B and C) IFN treatment.
Huh7.5 cells were infected with ﬁrst passage virus, treated with IFN-α2b at different con-
centration at 24 and 48 h post infection, and ﬁxed at 72 h to determine the number of
infected cells (see Materials and methods). The data are shown as the mean±SEM of
infected cells from triplicate infections in the experiment, relative to respective infection
in mock-treated controls (100%).
Fig. 7. A 2a 5′UTR-NS2 virus with one cytidine insertion between nucleotides 1 and 5 of
the 5′UTR was inhibited by miR-122 antagonism. Huh7.5 cells were transfected with
miR-122 antisense LNA SPC3649 at concentration of 0.4 nM (Li et al., 2011), and then
infected with ﬁrst passage 2a-Ins1C virus for 48 h. The FFU counts were determined
and presented as percentage relative to the respective infection in SPC3649-free
mock transfection controls (100%); values are means of triplicate infections±SEM
(see Material and methods). A 2a 5′UTR-NS2 recombinant with wild-type 5′UTR and
a resistant mutant Cell-U3 which contains U3 small nucleolar RNA insertion replacing
5′UTR SLI and miR-122 binding site 1 (Li et al., 2011) were included for comparison. A
and B; two independent experiments.
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systems may be attributed to different RNA replication efﬁciency, as in
general full-length HCV RNA replication was slightly lower than subge-
nomic RNA replication [reviewed in (Blight and Norgard, 2006)], which
may lead to a systematic difference. In addition, production of HCV in
cultured cells might be inﬂuenced by multiple functions in the HCV
life cycle. The replicon systemonly allows for studies of RNA replication,
while the functional signiﬁcance of these genotype-speciﬁc signals in
the complete HCV life cycle could not be studied. Therefore, the differ-
ent replication efﬁciency observed between 5′UTR of genotypes 1a
(H77) and 2a (JFH1 and J6) (Binder et al., 2007)might not lead to signif-
icant differences in production of infectious HCV particles in Huh7.5
cells. Future studies with parallel comparison of various genotype
5′UTRs in the context of replicon systems may be required to further
address these differences.
The 5′UTR is involved in long-range RNA-RNA interaction with
coding sequences and with the 3′UTR of the HCV genome, regulating
viral RNA replication and translation (Honda et al., 1999b; Kim et al.,
2003; Romero-Lopez and Berzal-Herranz, 2009). The viability and ge-
netic stability of our previously developed JFH1-based HCV genotypes
1–6 5′UTR-NS2 recombinants, which all contained NS3-3′UTR of
JFH1, indicated that the 5′UTR did not interact with the NS3-3′UTR
region in a genotype-speciﬁc manner important for virus production.
This notion was further conﬁrmed here by the fact that J6/JFH1
recombinants with the 5′UTR of genotypes 1–6 were fully functional
(Fig. 3). Importantly, full viability of J6/JFH1 recombinants with 5′UTR
of genotypes 1–6 (Fig. 3) and HCV genotypes 1–7 Core-NS2 recombi-
nants with 5′UTR of 1a and 3a (Fig. 2) also indicated that the 5′UTR
did not interact with the Core-NS2 region in a genotype-speciﬁc man-
ner essential for HCV production. Indeed, the nucleotides involved in
the interaction between 5′UTR IIId and the internal loop of NS5BSL3.2
(or SL9266) in in vitro binding assays (Romero-Lopez and Berzal-
Herranz, 2009) were highly conserved among HCV genotypes. Previous
reports described that the translation efﬁciency of a 1a 5′UTRwas lower
(Buratti et al., 1997) or similar (Collier et al., 1998; Motazakker et al.,
2007) to that of a 3a 5′UTR in in vitro reporter systems. Full viability of
HCV recombinants with the 5′UTR of 1a or 3a suggested that the poten-
tial differences in translation efﬁciency between the 1a and 3a 5′UTR
did not affect the production of JFH1-based HCV recombinant viruses
(Figs. 2 and 3). Overall, it appears that in vitro the nucleotide heteroge-
neities among the 5′UTR of different genotypes do not result in detect-
able biological differences, while the conserved regions of the 5′UTRmay be evolutionarily selected with important function for all HCV ge-
notypes and isolates.
Previous in vitro competition binding assays showed that interac-
tions existed between 5′UTR domains II and IV, as well as domains II
and IIIabcd (Lafuente et al., 2002). With fully functional JFH1-based
HCV culture systems, we demonstrated that J6/JFH1 recombinant
virus with heterotypic 5′UTR of chimeric domains I, II or III of geno-
types 1a and 3a were fully viable (Fig. 5); similarly, exchanging
5′UTR domain I with genotypes 1–6 did not affect the viability of
the 1a 5′UTR-NS2 recombinant virus (Fig. 4). Thus, the 5′UTR domain
I, II or III has no genotype-speciﬁc functions or interactions that signiﬁ-
cantly inﬂuence the viability of HCV recombinant viruses in Huh7.5
cells.
The 5′UTR of HCVwas reported to bind numerous cellular proteins
[reviewed in (Shi and Lai, 2006)], including retinoic acid inducible
gene I (RIG-I), an interferon-inducible cellular DExD/H box RNA
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weak inducer, RIG-I interaction with HCV pathogen-associated mo-
lecular patterns, such as HCV RNA 5′ triphosphate and 3′UTR polyU/
UC tracts, triggers intracellular signaling cascades to drive IFN pro-
duction and the expression of IFN-stimulated genes, thus forming in-
nate antiviral immune defenses to limit HCV infection [(Saito et al.,
2008) and reviewed in (Horner and Gale, 2009)]. However, unlike
original Huh7 cells, derivative Huh7.5 cells are defective in the RIG-I
pathway, which may contribute to its high permissiveness to HCV
replication (Sumpter et al., 2005). Previous studies have shown that
the spread of JFH1 infection was impaired in Huh7 cells (Wakita et
al., 2005; Zhong et al., 2005); no infectivity could be detected in the
supernatant of infected Huh7 cells up to 6 days after inoculation
(Zhong et al., 2005). Nonetheless, it would also be interesting in fu-
ture studies to investigate whether the differences in replication
and translation efﬁciency of the 5′UTRs observed previously (Binder
et al., 2007; Buratti et al., 1997; Honda et al., 1999b) could affect the
ability of the JFH1-based HCV recombinants with different genotype
5′UTRs (Fig. 3) to establish infections and if these 5′UTR recombinant
viruses induce IFN response in Huh7 cells in a genotype speciﬁc man-
ner. In addition to interaction with cellular factors, the 5′UTR also in-
teracts with HCV proteins, for instance, the sequences in 5′UTR
domains I (Tanaka et al., 2000) and III (Hwang et al., 1995; Tanaka
et al., 2000; Yu et al., 2009) have been shown to bind to the HCV
Core protein. The Core-NS2 recombinants with the 5′UTR of different
genotypes (Fig. 2A), especially the panel of J6/JFH1 recombinants
with the 5′UTR of genotypes 1–6 (Fig. 3A), provide a unique tool to
study potential interactions of the 5′UTR and viral or host factors in
a genotype-speciﬁc manner and in the setting of the complete HCV
life cycle.
Synthesis of the HCV RNA positive strand is supposed to be
directed by an intermediate minus strand through the function of
RNA-dependent RNA polymerase (RdRp), within the NS5B protein
(Moradpour et al., 2007). De novo initiation is believed to be the mech-
anism for HCV replication in vivo, since authentic 5′ and 3′-terminal nu-
cleotides are produced (Chinnaswamy et al., 2010; Luo et al., 2000;
Zhong et al., 2000b). In de novo RNA synthesis assays performed with
recombinant HCV NS5B, nucleotides A and G were favorable initiation
nucleotides (Luo et al., 2000; Zhong et al., 2000a, 2000b), and both, A
and G, were found at the 5′-terminus of HCV clinical isolates (HCV data-
bases and (Cai et al., 2004)). However, we observed that genomes from
culture-recovered JFH1-based recombinant viruses, generated in this
study or in a previous study (Li et al., 2011), all had A at the 5′-terminus.
Further reverse genetics studies demonstrated that A at the 5′-terminus
was required for JFH1-based HCV recombinants in Huh7.5 cells (Fig. 6).
The change of the 5′-terminal nucleotide also seems to be a highly likely
event, as all the recombinant viruses with mutated 5′-terminal nucleo-
tide spread efﬁciently after RNA transfection (Figs. 2 and 6), suggesting
that HCV possesses an efﬁcient terminus-repairing mechanism. Similar
observations were previously reported in the Con1 (1b) replicon sys-
tem, inwhich the 5′-terminal Gwas changed to A uponmultiple rounds
of replication, while A was stably maintained (Cai et al., 2004). Howev-
er, we previously found that the HCV genotype 1a H77C genome recov-
ered from acute phase of infection in an intrahepatically transfected
chimpanzee maintained the 5′-terminal G (Li et al., 2011; Yanagi et
al., 1997). The discrepancy in the 5′-terminal nucleotide observed for
in vitro- and in vivo-derived HCV might be due to the structural differ-
ences of HCV RdRp NS5B between HCV isolates. The JFH1-based recom-
binants tested all contained JFH1 RdRp, and prototype JFH1 strain has A
at the 5′-terminus (Kato et al., 2001). Thus, the JFH1 RdRpmight prefer-
ably select A as initiation nucleotide for JFH1-based recombinants dur-
ing replication cycles. Alternatively, A at the 5′-terminus could be an
in vitro effect, as the cultured hepatoma cells constitute a population
with relatively low complexity, which may restrict the selection of the
initiation nucleotide. In contrast, in vivo HCV replication may take
place in various cell types in the liver or other tissues with differentnucleotide concentrations, or with certain host proteins required for in-
corporating a guanine at the 5′ end. Thus, both A and G could be select-
ed to initiate the RNA synthesis in vivo. Nevertheless, parallel analysis of
the 5′G-containing JFH1-based HCV recombinants derived from in vitro
and in vivo systems, such as the genotype 2b (J8) 5′UTR-NS2 recombi-
nant that did not require adaptive mutations (Gottwein et al., 2009; Li
et al., 2011), would help to further clarify this issue. A recent report
speculated that G or A at the 5′-terminus of HCV was selected due to
the requirement of base-pairing with U at position 17 of the miR-122
molecule by forming a G-U wobble or a canonical A-U base pair
(Machlin et al., 2011). However, this hypothesis could not directly ex-
plain why this change occurred in culture-derived JFH1-based HCV
recombinants, but not in chimpanzee infection-derived full-length
HCV (Li et al., 2011; Yanagi et al., 1997). Given that the original Huh7
cells were shown to produce lessmiR-122 than produced in liver tissue
(Chang et al., 2004; Jopling et al., 2005), it could be further speculated
that A at the 5′-terminus facilitate the A-U base-pair, which could com-
pensate for the lack of in vivo host factors beneﬁcial for HCV replication
in a 5′ G-U base pair dependent manner, to adapt to a lowmiR-122 en-
vironment in cultured Huh7.5 cells.
To date, the mechanism of HCV genotype-dependent IFN resis-
tance is unclear. Development of JFH1-based HCV recombinants
with speciﬁc HCV genome regions of various genotypes allowed us
to test its role for IFN treatment in a genotype-speciﬁc manner. We
have previously demonstrated that Core-NS2 (Gottwein et al.,
2009), the NS3/NS4A protease (Gottwein et al., 2011) and NS5A
(Scheel et al., 2011b) were not linked to differential responses to
IFN-α2b treatment in Huh7.5 cells. Through IFN-α2b treatment of
the cultures infected with J6/JFH1 recombinant viruses with 5′UTR
of genotypes 1–6, here we demonstrated that the 5′UTR of HCV geno-
types 1–6 did not confer genotype-speciﬁc responses to IFN-α2b
treatment (Fig. 8). The data suggested that the 5′UTR may not confer
a genotype-speciﬁc IFN resistance. It remains to be determined
whether other viral elements might be involved in the genotype-
speciﬁc IFN resistance observed in patients. However, it is possible
that IFN resistance required the presence of multiple elements, thus,
it will be interesting to combine the potential IFN resistant elements,
such as genotype-speciﬁc 5′UTR and NS5A, in a JFH1-based recombi-
nant in the treatment. Alternatively, however, our short-term IFN
treatment assay might not be suitable to reveal an IFN resistance
phenotype.
In summary, we have demonstrated a non-genotype-speciﬁc role
of the 5′UTR in production of infectious HCV in vitro. We also demon-
strated that the 5′UTR might not account for the HCV genotype-
speciﬁc responses to IFN treatment. The developed HCV recombi-
nants with genotypes 1–6 speciﬁc 5′UTR would be optimal systems
to study genotype-speciﬁc interactions of the 5′UTR with cellular pro-
teins or testing of novel 5′UTR-based antivirals. This study advances
our understanding of the 5′UTR of different genotypes in the com-
plete HCV life cycle and contributes valuable information for future
HCV basic research and HCV drug development.
Materials and methods
Construction of JFH1-based HCV Core-NS2 recombinants with 5′UTR of
different genotypes and derivative mutant recombinants
The 5′UTR sequences of HCV genotypes 1a (strain H77), 1b (J4), 2a
(J6), 2b (J8), 3a (S52), 4a (ED43), 5a (SA13) and 6a (HK6a) were
obtained as previously described (Li et al., 2011). The JFH1 5′UTR of
previously developed JFH1-based Core-NS2 recombinants H77C/
JFH1V787A,Q1247L (1a) (Scheel et al., 2008), J4/JFH1F886L,Q1496L (genotype
1b) (Gottwein et al., 2009), J6/JFH (2a) (Lindenbach et al., 2005), J8/
JFH1 (2b) (Gottwein et al., 2009), S52/JFH1I793S,K1404Q (3a) (Gottwein
et al., 2009), ED43/JFH1-γT827A,T977S (4a) (Scheel et al., 2008), SA13/
JFH1A1022G,K1119R (5a) (Jensen et al., 2008), HK6a/JFH1F350S,N417T (6a)
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replaced with the 5′UTR of genotypes 1a (strain H77) or 3a (strain S52)
to generate corresponding recombinants with heterotypic 5′UTR of 1a
or 3a (Fig. 2A). The JFH1 5′UTR of 2a Core-NS2 recombinant (J6/JFH1)
(Lindenbach et al., 2005) was also replaced by the 5′UTR of genotypes
1b (strain J4), 2b (J8), 4a (ED43), 5a (SA13) and 6a (HK6a) (Fig. 3A).
To construct JFH1-based HCV recombinants containing heterotyp-
ic 5′UTR domains I, II or III the 5′UTR fragments with heterotypic do-
mains were chemically synthesized (GenScript, USA) and cloned into
appropriate recombinants. The HCV recombinants with 5′-terminal
nucleotide mutations were constructed by site-directed PCR muta-
genesis. A T7 promoter sequence TAATACGACTCACTATA was added
immediately upstream of the 5′UTR to enable in vitro transcription.
A guanine was inserted between the T7 promoter and the 5′UTR in
the cases when the 5′-terminal nucleotide of the 5′UTR was adenine,
unless otherwise stated. The entire HCV sequence for ﬁnal plasmid
constructs tested in Figs. 2, 3 and 6 was conﬁrmed by sequence anal-
ysis (except 2a-A1Δ in Fig. 6, see below) (Macrogen, Korea). The ﬁnal
maxi preparations of other plasmids used in the study and the 2a-
A1Δ were conﬁrmed by sequencing the T7 promoter and the entire
5′UTR sequence.
Transfection and infection of Huh7.5 cells
The human hepatoma cell line Huh7.5 was cultured as previously
described (Gottwein et al., 2007; Lindenbach et al., 2005). For trans-
fection, 10 μg of recombinant plasmid DNA was linearized with XbaI
(New England Biolabs) and treated with Mung Bean Nuclease (New
England Biolabs). RNA transcripts were generated from puriﬁed
DNA using T7 RNA Polymerase (Promega) and used for transfection
of Huh7.5 cells plated in 6-well plates ~24 h before transfection
using Lipofectamine 2000 (Invitrogen). The transfection complexes
were incubated with cells in OptiMEM medium (Invitrogen) for
~16 h, unless otherwise stated. The cells were then sub-cultured
every 2–3 days; the supernatant was collected, ﬁltered (0.45 μm)
and stored at −80 °C. To passage viruses, naïve Huh7.5 cells at
~80% conﬂuence in T25 ﬂask were incubated with 1 ml cell-free
virus-containing transfection-derived supernatant. For comparative
growth kinetics studies, naïve Huh7.5 cells were infected with virus
with an MOI of 0.003 FFU/cell.
Determination of virus infection and HCV infectivity titers
HCV infections in transfected or infected cultures were detected
by immunostaining for HCV NS5A. Infected cells were grown in
chamber slides, ﬁxed with acetone (−20 °C) and incubated with pri-
mary monoclonal antibody anti-NS5A, 9E10 (Lindenbach et al., 2005),
at 1:250 dilution in PBS with 1% BSA. The secondary antibody was
Alexa Fluor 594 goat anti-mouse IgG (H+L) (Invitrogen) diluted in
PBS with 0.1% Tween-20 at 1:500. Hoechst 33342 (Invitrogen) was
used at a 1:10,000 dilution for staining of cell nuclei. The percentage
of HCV infected cells was examined by confocal microscopy and
used to follow the status of HCV infection in the culture.
For titration of the virus infectivity, 6×103 naïve Huh7.5 cells per
well were grown in polylysine coated Nunc 96 Well™ Optical Bottom
Plate (Nunc, Denmark) for 24 h in 200 μL complete growth medium.
The cells were then infected with 100 μL of 2-fold or higher serial
dilution of the virus-containing supernatants in triplicate for each di-
lution and incubated for 48 h. The cells were ﬁxed with methanol
(−20 °C), and HCV infected cells were detected by immunostaining
for NS5A. The primary antibody anti-NS5A 9E10 (Lindenbach et al.,
2005), was used at a 1:1000 dilution in PBS with 0.1% Tween-20; the
secondary antibody ECL horseradish-peroxidase-linked anti-mouse im-
munoglobulin G (GE Healthcare) was diluted 1:300 in PBS with 0.1%
Tween-20. Horseradish-peroxidase substrate (DAB Substrate Kit,
Dako) was used for focus forming unit (FFU) stainings. The number ofFFU was manually counted using a light microscope or automatically
counted by an ImmunoSpot Series 5 UV Analyzer with customized soft-
ware (CTL Europe GmbH) (Gottwein et al., 2010). In automated count-
ing, themean FFU count of 3–6 negativewells was always below 15 and
was subtracted from FFU counts in each experimental well. Detection
cutoff was set to the mean FFU count of negative control wells plus 3
standard deviations (SD) plus 3. Counts of up to 200 FFU/well were in
the linear range of test dilution series and comparable tomanual counts.
The viral infectivity titer is presented as FFU/mL of supernatant aver-
aged from three independent dilutions.
Determination of HCV RNA titers
HCV RNA was puriﬁed from 200 μl cell-free supernatant using the
Total Nucleic Acid Isolation Kit (Roche Applied Science). HCV RNA ti-
ters were determined using real time RT-PCR TaqMan assay as previ-
ously described (Gottwein et al., 2007) and are given as international
units per milliliter (IU/mL) of supernatant.
Sequence analysis of the ORF of recovered HCV
Virus RNA extracted from ﬁrst passage supernatant was subjected
to nested RT-PCR followed by direct sequencing of twelve overlap-
ping second round PCR products as previously described (Gottwein
et al., 2007, 2009; Jensen et al., 2008; Scheel et al., 2008; Yanagi et
al., 1997) or direct sequencing of four overlapping second round
PCR products. To generate four overlapping PCR products the reverse
transcription of HCV RNA was performed as previously described
(Gottwein et al., 2007, 2009; Jensen et al., 2008; Scheel et al., 2008;
Yanagi et al., 1997), the ﬁrst round PCR was done using forward
primers 5′UTRF40, 5′-CTCCCCTGTGAGGAACTACTGTCTTCACGC-3′, spe-
ciﬁc to 5′UTR of genotypes 1a, 1b, 2a, 2b, 4a, 5a and 6a, or primer 3a5′
UTRF38, 5′-CTCCCCTGTGAGGAACTTCTGTCTTCACGC-3′, for genotype
3a 5′UTR and all with previously described reverse primer 9470R(24)
_JFH1, 5′-CTATGGAGTGTACCTAGTGTGTGC-3′ (Gottwein et al., 2007).
The second round PCR generating four overlapping amplicons was
done using primers 5′UTRF74, 5′-GCGTCTAGCCATGGCGTTAGTAT-
GAGTGT-3′, speciﬁc to the 5′UTR of genotypes 1a, 1b, 2a, 2b, 4a,
5a and 6a, or 5'UTRF74_3a, 5′-GCGCCTAGCCATGGCGTTAGTACGAGTGT-
3′, speciﬁc to the 3a 5′UTR, and reverse primer JR3952, 5′-
AAGTGGGAGACCTTGTAACAACGTCGAGT-3′, for amplicon one; primers
JF3703, 5′-CAAGTCTTTGGAGCCGTGCAAGTGT-3′, and JR7356, 5′-
AGTTGCTGGAGGGCTTCTGATATGG-3′, for amplicon two; previously de-
scribed primers 6862S_JFH1, 5′-TGGGCACGGCCTGACTACAA-3′, and
7848R_JFH1, 5′- GGCCATTTTCTCGCAGACCCGGAC-3′, for amplicon three
(Gottwein et al., 2007); primer 7741S_J6 5′-ATGGCCAAAAAT-
GAGGTGTTCTGC-3′ (Gottwein et al., 2007), and JR9446 5′-CAGTTAGC-
TATGGAGTGTACCTAGTGTGTGCC-3′, for amplicon four.
Rapid ampliﬁcation of 5′ complementary DNA ends (5′RACE)
The 5′RACESystem for RapidAmpliﬁcation of cDNAEnds (Invitrogen)
with dA or dC tailing technology was used to determine the 5′UTR and
3′UTR sequences of recovered HCV as previously described (Li et al.,
2011). To determine the 5′UTR of the virus, 200 μl virus-containing cul-
ture supernatant was used for RNA extraction using TRIzol LS Reagent
(Invitrogen). The 5′RACE with dA-tailing procedure was performed on
the HCV RNA positive strand. The second round PCR products were se-
quenced directly or cloned into pCR2.1-TOPO (Invitrogen) for sequenc-
ing. For sequence analysis of the 3′UTR, total RNA was extracted from
HCV infected cells using TRIzol Reagent (Invitrogen). The 5′RACE
with dC tailing technology was conducted on the HCV RNA negative
strand. The PCR products were puriﬁed and cloned into pCR2.1-TOPO
(Invitrogen) for sequencing. The consensus sequence was considered
to reﬂect the 3′UTR sequence of recovered HCV.
233Y.-P. Li et al. / Virology 421 (2011) 222–234To determine the 5′UTR of RNA transcripts, one aliquot of RNA
transcription products used for transfection was puriﬁed by RNeasy
Mini Kit (Qiagen), reverse transcribed, and the cDNA was tailed
with dA for the transcripts with A, G, C, and U at the 5′-terminus,
and in addition with dC for the transcripts with U at the 5′-terminus.
Second round PCR products were directly sequenced to determine
the entire 5′UTR sequence; in case of unclear direct sequencing
reads, the PCR products were cloned for sequence analysis to deter-
mine the 5′UTR sequence of the RNA transcripts.
LNA transfection and virus infection
Transfection of Huh7.5 cells with miR-122 antisense LNA and sub-
sequent determination of virus infection were performed as previous-
ly described (Li et al., 2011).
Interferon treatment
Huh7.5 cells were seeded in 96-well Nunc 96 Well™ Optical Bot-
tom plates (Nunc) at a density of 5×103 cells/well in 200 μl growth
medium. After 24 h, the cells were infected with 190 μl virus dilutions
that had been pre-warmed at 37 °C for 1 h, and incubated for 24 h.
The cultures were treated with 190 μl growth medium containing
IFN-α2b at speciﬁed concentrations 24 and 48 h after infection.
After another 24 h the cultures were ﬁxed with methanol (−20 °C).
The number of single infected cells was visualized by immunostaining
for HCV NS5A (see above) and counted by ImmunoSpot Series 5 UV
Analyzer with customized software (Scheel et al., 2011b).
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